勘误：利奥西呱替代磷酸二酯酶-5抑制剂治疗肺动脉高压患者的疗效和安全性：一项系统评价与荟萃分析。
Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis.
作者信息
Liu Yu-Yang, Qu Yi-Yang, Wang Shang, Luo Ci-Jun, Qiu Hong-Ling, Li Hui-Ting, Yuan Ping, Wang Lan, Li Jin-Ling, Jiang Rong, Zhang Rui
机构信息
Department of Cardiopulmonary Circulation, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Department of Cardiology, Affiliated Hospital of Qingdao University, Qingdao, China.
出版信息
Front Pharmacol. 2023 Feb 20;14:1155631. doi: 10.3389/fphar.2023.1155631. eCollection 2023.
Abstract
[This corrects the article DOI: 10.3389/fphar.2023.1052546.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fphar.2023.1052546。]
相似文献
1
Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis.勘误：利奥西呱替代磷酸二酯酶-5抑制剂治疗肺动脉高压患者的疗效和安全性：一项系统评价与荟萃分析。
Front Pharmacol. 2023 Feb 20;14:1155631. doi: 10.3389/fphar.2023.1155631. eCollection 2023.
2
Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis.利奥西呱替代磷酸二酯酶-5抑制剂治疗肺动脉高压患者的疗效和安全性：一项系统评价和荟萃分析。
Front Pharmacol. 2023 Jan 26;14:1052546. doi: 10.3389/fphar.2023.1052546. eCollection 2023.
3
Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.口服靶向治疗药物在肺动脉高压治疗中的应用：一项临床试验的荟萃分析
Pulm Pharmacol Ther. 2014 Dec;29(2):241-9. doi: 10.1016/j.pupt.2014.08.005. Epub 2014 Aug 27.
4
[Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat].[肺动脉高压特异性治疗的优化：利奥西呱的应用可能性]
Ter Arkh. 2021 Sep 15;93(9):1117-1124. doi: 10.26442/00403660.2021.09.201014.
5
Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat.病例报告：一名肺动脉高压患者从磷酸二酯酶-5抑制剂转换为利奥西呱治疗。
BMC Pulm Med. 2016 May 18;16(1):82. doi: 10.1186/s12890-016-0229-x.
6
Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.RESPITE研究的原理与设计：一项开放标签的3b期研究，针对对磷酸二酯酶-5抑制剂治疗反应不足的肺动脉高压患者使用利奥西呱。
Respir Med. 2017 Jan;122 Suppl 1:S18-S22. doi: 10.1016/j.rmed.2016.11.001. Epub 2016 Nov 5.
7
Riociguat therapy for pulmonary hypertension: a systematic review and meta-analysis.利奥西呱治疗肺动脉高压：系统评价和荟萃分析。
Ann Palliat Med. 2021 Oct;10(10):11117-11128. doi: 10.21037/apm-21-2656.
8
Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model.勘误：在SUGEN5416/低氧大鼠模型中，TAK-1抑制剂作为单一疗法或作为利奥西呱的附加疗法对代谢重编程和肺动脉高压的影响。
Front Pharmacol. 2023 Jun 12;14:1228923. doi: 10.3389/fphar.2023.1228923. eCollection 2023.
9
Corrigendum for efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies).利奥西呱在肺动脉高压患者联合治疗中的疗效与安全性勘误（PATENT研究）
Pulm Circ. 2023 Jun 22;13(2):e12250. doi: 10.1002/pul2.12250. eCollection 2023 Apr.
10
Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.利奥西呱用于慢性血栓栓塞性肺动脉高压患者：从5型磷酸二酯酶抑制剂转换用药的有效性
Respir Investig. 2017 Jul;55(4):270-275. doi: 10.1016/j.resinv.2017.04.004. Epub 2017 Jun 19.
Zotero 插件